Site Search
Skip navigation

Global Technology Innovators

It is our mission to revolutionize molecular design by dramatically improving efficiency and predictive accuracy, while substantially reducing the time and costs of the development and commercialization of new molecular entities.

LITMUS Antipsychotic Compound Bank ("LACB")

Spectral Modeling™

Spectral Modeling™ is an innovative computational method initially developed at FDA's National Center for Toxicological Research for in silico screening purposes. LITMUS Molecular Design, LLC ("LMD") holds exclusive worldwide rights to the commercialization and development of Spectral Modeling™ technology.

Spectral Modeling™ utilizes computer-based mathematical methods to analyze spectral data for identification of spectral attributes that are highly predictive of a molecule's biological, chemical, and physical activities.  Spectral Modeling™ is a marked departure from QSAR and previous methodologies utilized to develop new molecular entities.

The LACB represents the first bank of compounds developed by LMD for auction. LMD anticipates that it will develop additional banks of compounds for other classes of drugs in different therapeutic areas on a quarterly basis which will also be offered through similar auction procedures. In addition, LMD is currently accepting proposals for collaboration agreements to develop compounds for specific therapeutic areas.

Proprietary LITMUS Models

Further development and refinement of computational techniques has allowed LMD to extend the application of Spectral Modeling™ to exploitation of computational results for designing structures with targeted activities and to potentially reduce side effects. The following proprietary LMD Models have been developed:

 

The LACB

Using results acquired during the modeling process, a series of 125 antipsychotic drug candidates were designed and submitted to all models for prediction.  Of the 125 drug candidates, 104 were predicted to have antipsychotic activity and 26 had desirable receptor-binding ratios for atypical antipsychotic activity.  Of these 26 atypical antipsychotic drug candidates, two (LMD-00060 and LMD-00076) were selected for synthesis and in vitro and in vivo testing.  Receptor-binding results have confirmed the desired activity at Dopamine 2 and Serotonin 2A receptors with experimental affinities being within 11% of the predicted affinities.

The entire LITMUS Antipsychotic Compound Bank (LACB) is available for licensing (all antipsychotic drug candidates as a whole). The predicted biological, clinical, and toxicology profiles for all antipsychotic drug candidates can be examined or downloaded at the links below.

The LACB (.pdf format) The LACB (.xls format)

Disclaimer: While LMD has taken extra ordinary steps to assure the data in the listing is without error, we cannot provide absolute assurance that unintentional and inadvertent errors do not exist.

 

Submission of Licensing Offers

LITMUS Molecular Design (LMD) is accepting for consideration licensing offers to be submitted under the following criteria:

The licensing proposal should follow the standard pharmaceutical licensing deal structure of upfront fees (minimum USD $5 million), milestone payments, and royalties upon commercialization.

  • 1) Please submit an outline of the basic deal structure including a calculation of the total estimated value and present value of the proposed deal structure to LMD (use a discount rate of 1% per month). Hence proposals should include dates of anticipated milestone achievements.
  • 2) Details of milestone definitions and other events will be subject to negotiation. However, milestone payments should be based on the number of compounds achieving a milestone and not on the basis of the milestone reached, e.g. Upon achievement of milestone "A"  LICENSEE to pay LMD $X per compound up to Y compounds, where X is the amount to be paid per compound and Y is the maximum number of compounds for which the LICENSEE will incur this liability.
  • 3) LMD will not disclose any information regarding received proposals.
  • 4) The deadline for proposal submission is July 31, 2008. LMD will review proposals for completeness upon receipt and perform the analytical review of bids beginning August 1, 2008. Depending on the number of proposals received, announcement of the offer accepted will be made on or about August 18, 2008.
  • 5) LMD will respond to questions regarding the antipsychotic drug candidates and their discovery.  Disclaimer: Even though, the in vitro/in vivo experimental results obtained for two compounds selected from the LACB confirm the predictive accuracy of our techniques, LMD cannot guarantee that the antipsychotic drug candidates will have the predicted activities.
  • 6) Although LMD has conducted a preliminary review of the IP status of these compounds LMD cannot guarantee that any or all antipsychotic drug candidates are patentable. Upfront fees will be held in escrow until the LICENSEE's due diligence patent search has been conducted.
  • 7) LMD will patent the compounds in consultation with LICENSEE and at LICENSEE's expense.
  • 8) The LICENSEE shall have a first right of refusal option on any future antipsychotic drug candidates created by LMD.

 

Submit all licensing proposals (via mail or express delivery) to:

LITMUS Molecular Design
c/o Marc Rieke
9821 Katy Freeway
Suite 500
Houston, TX 77024
(713) 464-7770

 

and notifications of proposal submission or intentions to bid, and questions regarding the antipsychotic drug candidates should be sent to:

Bill W. Massey, Ph.D.
President, LITMUS Molecular Design, LLC
Ramona, California USA
Phone: 760.440.9390
bmassey@litmusgti.com

 

Also, visit  www.litmusmoleculardesign.com  for in-depth technical information and white papers on Spectral Modeling™